NasdaqCM - Delayed Quote USD

Windtree Therapeutics, Inc. (WINT)

0.7899
-0.0381
(-4.60%)
At close: 4:00:01 PM EDT
0.7752
-0.01
(-1.86%)
After hours: 6:27:57 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for WINT

Recent News: WINT

View More
Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference
GlobeNewswire 10 hours ago
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates
GlobeNewswire 3 days ago
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
GlobeNewswire 7 days ago
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
GlobeNewswire 13 days ago
Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development

Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development
GlobeNewswire 18 days ago
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates
GlobeNewswire last month
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
PR Newswire last month
Evofem Reports Fourth Consecutive Year of Net Sales Growth

Evofem Reports Fourth Consecutive Year of Net Sales Growth
PR Newswire last month
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
GlobeNewswire last month
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
GlobeNewswire last month
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage

WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage
Zacks Small Cap Research 2 months ago
View More

Related Tickers

ADTX Aditxt, Inc.
1.7500
+5.42%
 
GRI GRI Bio, Inc.
1.4000
-6.67%
 
HEPA Hepion Pharmaceuticals, Inc.
0.1050
-4.81%
 
DRMA Dermata Therapeutics, Inc.
0.8300
+4.93%
 
PBM Psyence Biomedical Ltd.
6.01
+15.58%
 
AEON AEON Biopharma, Inc.
0.5094
+1.88%
 
OSRH OSR Holdings, Inc.
1.1300
-0.88%
 
PSTV Plus Therapeutics, Inc.
0.3350
-20.24%
 
ZVSA ZyVersa Therapeutics, Inc.
0.5229
0.00%
 
RLMD Relmada Therapeutics, Inc.
0.5090
+10.41%